Google
MGNX Stock Analysis — MACROGENICS INC (Healthcare >> Biotechnology)
MGNX FAQ
What is MGNX's P/E ratio?
MACROGENICS INC (MGNX) currently trades at a P/E ratio of 14.28.
What is MGNX's ROE?
MACROGENICS INC reports a Return on Equity (ROE) of -331.91%.
What is MGNX's dividend yield?
MACROGENICS INC offers a dividend yield of 0.00%.
What is MGNX's Quality Score?
Our AI rates MGNX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MGNX?
Our AI Timing Score for MGNX is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MGNX belong to?
MACROGENICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
MGNX AI Analysis Summary
Our AI summary for MGNX: MACROGENICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 14.28, ROE of -331.91%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.69
Price
-0.09
(-2.38%)
Day Change
|
|
|---|
MGNX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.69 |
| PBV / Sector |
11.33 / 5.20
|
| Earning Per Share | -1.08 |
| PE / Sector |
14.28 / 19.97
|
| PEG or PE/Growth / Sector |
0.08 / 1.22
GREAT
|
| Average 1M Daily Value |
3.47 M
GREAT
|
| Average 1W Daily Value |
2.02 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:10 |
| Symbol | MGNX |
| Name | MACROGENICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 63.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 240.27 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850
Phone: 301 251 5172
Website: https://www.macrogenics.com
Employees: 293
Sector: Healthcare >> Biotechnology
Description: MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap